Pharmacology, Toxicology and Pharmaceutical Science
Heart Failure with Preserved Ejection Fraction
100%
Acute Heart Failure
85%
Cardiovascular Disease
78%
Heart Failure with Reduced Ejection Fraction
50%
Low Density Lipoprotein Cholesterol
50%
Pitavastatin
50%
Statin (Protein)
50%
Fatty Acid Binding Protein
50%
Coronary Artery Disease
50%
Rivaroxaban
50%
Cardiovascular Risk
50%
Acetylsalicylic Acid
50%
D Dimer
50%
Creatinine
50%
Brain Natriuretic Peptide
50%
Adverse Outcome
50%
Acute Kidney Failure
50%
Myosin Binding Protein C
50%
Heart Failure
43%
Cause of Death
35%
Heart Left Ventricle Failure
25%
Population Study
13%
Acute Coronary Syndrome
10%
Chronic Kidney Failure
10%
Disease
10%
Bleeding
10%
End Stage Renal Disease
10%
Kidney Disease
10%
Cohort Study
7%
Vascular Disease
6%
Medicine and Dentistry
Acute Kidney Injury
100%
Heart Failure with Preserved Ejection Fraction
100%
Acute Decompensated Heart Failure
68%
Creatinine
56%
Heart Failure with Reduced Ejection Fraction
50%
Amino Terminal Sequence
50%
Intensive Care Unit
50%
Brain Natriuretic Peptide
50%
Adverse Outcome
50%
Cardiovascular System
50%
Percutaneous Coronary Intervention
50%
Urinary System
50%
Protein Z
50%
Proteinuria
50%
D-Dimer
50%
Heart Left Ventricle Ejection Fraction
33%
Ejection Fraction
33%
Heart Failure
27%
Cause of Death
18%
Proportional Hazards Model
18%
Risk Stratification
18%
Chronic Kidney Disease
10%
Nephropathy
10%
Acute Coronary Syndrome
10%
Kidney Transplantation
10%
Renal Replacement Therapy
10%
Disease
10%
End Stage Renal Disease
10%
Heart Left Ventricle Failure
8%
Two Dimensional Speckle Tracking Echocardiography
8%
Logistic Regression Analysis
6%
Population Research
6%
Keyphrases
Cardiac Intensive Care Unit
100%
Acute Kidney Injury
50%
Long-term Prognostic Value
50%
Adverse Outcomes
50%
Fatty
50%
Urinary Liver-type Fatty Acid Binding Protein
50%
Stable Cardiovascular Disease
50%
Liver Type
50%
Myosin-binding Protein C
50%
Creatinine
40%
Protein Level
30%
Reduced LVEF
16%
Heterogeneous Patients
10%
Risk Factors
10%
Prognostic Value
10%
End-stage Kidney Disease
10%
Serum Creatinine
10%
Endpoint Determination
10%
Non-surgical
10%
Reclassification
10%
All-cause Mortality
10%
Kaplan-Meier
10%
Stage 5 Chronic Kidney Disease
10%
Dialysis Treatment
10%
Kidney Transplantation
10%
Maintenance Dialysis
10%
Long-run Risk
10%
Acute Decompensated Heart Failure
10%
Hospital Admission
10%
Risk Stratification
10%
Acute Coronary Syndrome
10%
Multivariate Cox Regression Analysis
10%
Kidney Disease Improving Global Outcomes
10%
Atherosclerotic Vascular Disease
6%
Emergency Procedures
6%
12-month Mortality
5%
High-dose Statin Therapy
5%
Low-density Cholesterol
5%
